NCT06525168View on ClinicalTrials.gov

Safety, Tolerability and Pharmacokinetic Characteristics Evaluation on DA414

PHASE1RecruitingINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

February 6, 2024

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2026

Conditions
Ischemic Stroke
Interventions
DRUG

DA414 Granules

DA414 Granules single ascending doses. DA414 will be orally administrated at single ascending doses of 12.5 mg, 25mg, 50 mg, 100mg and 200 mg.

DRUG

DA414 placebo

DA414 placebo single ascending doses. DA414 placebowill be orally administrated at single ascending doses of 25mg, 50 mg, 100mg and 200 mg.

Trial Locations (1)

430000

RECRUITING

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, China, Wuhan

All Listed Sponsors
lead

Chendu DIAO Nine Hong Pharmaceutical Factory

INDUSTRY